{
    "clinical_study": {
        "@rank": "149840", 
        "arm_group": {
            "arm_group_label": "OPT-822/OPT-821", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving\n      Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian,\n      fallopian tube, or primary peritoneal cancer after cytoreductive surgery and platinum-based\n      chemotherapy as initial treatment for primary disease or as salvage treatment for first\n      relapse."
        }, 
        "brief_title": "Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer", 
        "completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female subjects \u2265 21 years of age with histologically confirmed \u2265 stage II epithelial\n             ovarian, fallopian tube, and primary peritoneal cancer at diagnosis\n\n          -  Who have not progressed after initial treatment with cytoreductive surgery and at\n             least 4 cycles of platinum-based chemotherapy.\n\n        OR\n\n          -  Female subjects \u2265 21 years of age with first relapsed epithelial ovarian, fallopian\n             tube, and primary peritoneal cancer (regardless of stage at diagnosis)\n\n          -  Who have not progressed after received at least 4 additional cycles of platinum-based\n             chemotherapy with or without having undergone secondary cytoreductive surgery .\n\n        Exclusion Criteria:\n\n          -  Subjects with evidence of disease progression according to the GCIG CA125 criteria or\n             RECIST 1.1 criteria.\n\n          -  Subjects who are currently receiving any other concomitant anticancer therapy.\n\n          -  Subjects with evidence of extra-abdominal metastasis."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132988", 
            "org_study_id": "MMH-OPT822-OC001"
        }, 
        "intervention": {
            "arm_group_label": "OPT-822/OPT-821", 
            "intervention_name": "OPT-822/OPT-821", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "fionaeg0528@gmail.com", 
                "last_name": "Fiona Chen", 
                "phone": "886-2-25433535", 
                "phone_ext": "3941"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "104"
                }, 
                "name": "Mackay Memorial Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Chih-Lung Chang, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yuh-Cheng Yang, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Labeled Phase II Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", 
        "overall_contact": {
            "email": "fionaeg0528@gmail.com", 
            "last_name": "Fiona Chen", 
            "phone": "886-2-25433535", 
            "phone_ext": "3941"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Until disease progression or up to 5 years after the enrollment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132988"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Disease Recurrence Rate", 
            "safety_issue": "No", 
            "time_frame": "At 2 years after the enrollment"
        }, 
        "source": "Mackay Memorial Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "OBI Pharma, Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Mackay Memorial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}